TheDinarian
News • Business • Investing & Finance
How Rockefeller Monopolized Medicine and Created BIG PHARMA
Please read and share, let the truth be known worldwide...
October 13, 2023
post photo preview

Born in 1839, John D. Rockefeller would go on to become one of the great robber barons and industrialist tycoons of American history. By the turn of the 20th century, Rockefeller controlled 90% of the oil refineries in the US through his company Standard Oil, becoming in the process America’s first billionaire.

Of course, in 1911, Standard Oil was ruled by the US Supreme Court to be an illegal monopoly in violation of antitrust laws and forced to break up. Like his father, John D. Rockefeller had built his success on illegality, cons, and scams.

Still, this was not enough for Rockefeller. He wanted more.

 

How Rockefeller Targeted Medicine

At the time, chemicals made from oil, known as ‘petrochemicals,’ were being discovered and developed in the US. This included the discovery that pharmaceutical drugs could be made from oil, which Rockefeller saw as an opportunity to expand his empire. The key was that petrochemicals, unlike natural health remedies, could be patented, presenting an enormous opportunity for Rockefeller profits.

There was only one problem – at the time, natural, herbal, and traditional medicines were very popular in the US. Something like half of the doctors and medical colleges in the country were using holistic medicine, natural remedies, and knowledge taken from Indigenous Native Americans. Rockefeller needed a way to eliminate the competition, to create a monopoly in medicine as he had done with oil.

And so, he went to his good friend Andrew Carnegie, another robber baron who had gotten rich through his monopoly of the steel industry and, incidentally, one of the country’s leading eugenicists. Together, the two men hatched a plan to take over American medicine.


maxresdefault.jpg

 

The Creation of Big Pharma

From the cover of the Carnegie Foundation, they would send a man named Abraham Flexner around the country to report on its medical colleges and hospitals. After visiting all 155 medical schools existing at that time in the US and Canada, he completed the seminal Flexner Report in 1910.

Following the directions of his employers, Flexner called in his report for a total restructuring of the American medical system, most specifically, for the pushing aside of natural and traditional remedies in favor of Rockefeller pharmaceuticals. The report even specifically mentioned the eradication of “dissidents,” appropriately, since this is exactly what happened.

Almost immediately after the report was issued, medical schools teaching things like naturopathy, homeopathy, electromagnetic field therapy, and so on, were told to drop these things or close. More than half of all medical colleges in the country did close, and many non-compliant doctors were demonized and even jailed.

But Rockefeller and Carnegie went further, offering huge grants to medical schools and hospitals so long as they only taught and practiced Rockefeller medicine, and allowed Rockefeller agents on their boards of directors to ensure compliance.

It was the carrot and the stick – those who agreed got funded with big money, those who didn’t were crushed.

In this way, all medical colleges in the country were streamlined and homogenized, with doctors all learning the same thing – how to use and prescribe Rockefeller’s patented drugs.

But, like any good monopolist, Rockefeller went further in seeking to consolidate his control. He took over the AMA and emboldened it as the gatekeeper of scientific thought and witch hunter of alternative medical practices. He took control of the FDA in order to control the approval process for new drugs. He even founded the American Cancer Society in 1913. Within a few short years, Rockefeller was in total control of the American medical system in both thought and action.

The result of this takeover, the product of this monopolist son of a conman and his eugenicist partner, would become known as “Big Pharma.”

That Big Pharma took over and monopolized American medicine, promoting their own patented, profit-making products and suppressing all others, isn’t even a conspiracy theory.

In fact, it was recorded for all to see in 1953 …

 

The Fitzgerald Report

In the early 1950s, US Senator Charles Toby enlisted an investigator with the Interstate Commerce Commission named Benedict Fitzgerald to examine allegations of conspiracy and monopoly in medicine. Toby had become interested in the issue after his own son had gotten cancer and been given less than two years to live by orthodox medicine before pursuing alternative treatments and being cured.

The resulting 1953 report, known as the Fitzgerald Report, was truly shocking. It concluded that Big Pharma had been involved in “a conspiracy of alarming proportions.”

First, there was

“The organized effort to hinder, suppress and restrict the free flow of drugs which allegedly proven successful in cases where clinical records, case history, pathological reports, and x-ray photographic proof, together with the alleged cured patients, are available.”

On top of that,

“Public and private funds have been thrown around like confetti at a country fair to close up and destroy clinics, hospitals, and research laboratories which do not conform to the viewpoint of medical associations.”

The report even noted that Big Pharma had conspired to suppress at least 12 promising cancer treatments, including mentioning Hoxsey Therapy by name.

It was an unfathomably damning report, making clear that the tentacles of a Big Pharma conspiracy to suppress alternative medicine were everywhere.

But as it turns out, the report did not go far enough

 

The Suppression of Laetril as a Cure for Cancer

Oftentimes when a new natural cancer treatment appears, the assertion from the medical establishment is that the new treatment is either unproven, or disproven. There is no better example of what this really means in the era of Big Pharma than the case of a cancer treatment called Laetrile.

In 1952, a year before the Fitzgerald Report, a biochemist named Ernst Krebs proposed that cancer was a deficiency disease which could be cured with a compound called amygdalin, found in over 1,200 plants, and most specifically in the seeds of apricots. By extracting this amygdalin from apricot kernels, Krebs created a product he called Laetrile.

Over the course of many years, Krebs conducted numerous lab experiments on animals which showed that Laetrile was an effective cancer treatment, that somehow, it caused cancer cells to self-destruct.

By the 1960s, a doctor named John Richardson had picked up the research, and had even begun treating human patients with Laetrile. Unsurprisingly, the Rockefeller-controlled FDA launched a massive media campaign against Richardson and Laetrile, claiming that the treatment was toxic and dangerous. By 1971, the FDA officially banned Laetrile, and, in 1972, they stormed Richardson’s clinic and arrested him.

But even after Richardson was jailed, people kept asking about Laetrile, writing to government officials, medical journals, and scientific labs demanding answers. At this point, Big Pharma knew they had to put their foot down once and for all. They needed to undertake official testing which proved that Laetrile didn’t work.

The testing would take place at Memorial Sloan-Kettering Cancer Center in New York City, and what would happen next would come to be described as “one of the biggest medical cover-ups the world of cancer research has ever seen.”

The tests would be led and directed by Dr. Kanematsu Sugiura, known at that time as “the preeminent cancer researcher in America.” He had over 60 years of experience, publishing hundreds of academic papers on the subject. As one scientist said, “When Dr. Sugiura publishes, we know we don’t have to repeat the study, for we would obtain the same results he has reported.”

In 1972, testing began, with Laetrile being administered to mice with many different types of cancerous tumors. At its completion, Dr. Sugiura concluded that Laetrile stopped the spread of cancer, inhibited the growth of tumors, and acted as a cancer prevention. It even provided relief from pain and improved general health.

This seemed to be incredible news. Except, there were three Rockefellers sitting on the board of Sloan-Kettering, as well as a dozen more people representing companies making big money from Big Pharma. When they caught word of the test results, “all hell broke loose,” and another round of tests was ordered.

Unfortunately for Sloan-Kettering executives, the second round of testing only confirmed the first. Except this time, with two confirmed tests from the legendary Dr. Sugiura in the books, mainstream media was forced to cover it. Had a cure for cancer really been found, they asked?

Sloan-Kettering officials refused to speak with the media, refused to discuss the results or answer any questions, saying only in a prewritten statement that a third round of tests had been ordered in order to “clarify” the results, as if they had not been twice clarified already.

In this third test, a new wrinkle would be introduced – Dr. Sugiura would be blinded. He would not know which half of the mice would be receiving Laetrile, and which half would be given a saline solution, as if this eminently respected scientist was going to somehow manipulate the results.

After four weeks, Dr. Sugiura could see which of the mice were being given Laetrile, since mice in some of the cages had fewer and smaller tumors, while mice in the other cages showed no effects. Sloan-Kettering overseers who were supervising the project confirmed to Dr. Sugiura that he was correct. For a third time, Laetrile’s cancer treating properties were confirmed.

Except, arguing that Dr. Sugiura was no longer blinded since he knew which cages were which, Sloan-Kettering officials shut the tests down.

They would try yet again to get the results they were looking for with a fourth test. This time, not only would Dr. Sugiura be blinded, but the mice who were receiving the treatment would be mixed together with those who weren’t. Dr. Sugiura warned that this was dangerous because there was no dependable way to ensure the lab techs administering the treatment would be able to identify the correct mice every time. And, in fact, this is exactly what happened. Some of the mice who were purportedly only being given a saline solution saw their tumors stop growing.

“There’s something funny here,” Dr. Sugiura professed. The ‘something funny’ was that the treatments had been mixed, with many mice receiving some Laetrile and some saline solution, just as Dr. Sugiura had predicted.

Yet, in this case, the legitimacy of the results wasn’t important to Sloan-Kettering’s Rockefeller board. Immediately, they announced that “results from the experiment do not confirm the earlier positive findings of Sugiura.”

Then, they called a press conference attended by most of mainstream media and declared, “Laetrile was found to possess neither preventive, nor tumor-regressant, nor anti metestatic, nor curative anti-cancer activity” – the exact opposite of what the first three tests had shown.

At the end of the press conference, the floor was opened to questions from the media, which is when things took a dramatic turn.

“Dr. Sugiura,” someone shouted, “Do you stick by your belief that Laetrile stops the spread of cancer?”

The room fell silent as the fabled Dr. Sugiura rose to his feet and replied, “I stick.”

The next month, Sloan-Kettering executives appeared before a Senate subcommittee hearing to decide the fate of Laetrile. While it had been banned by the FDA in 1971, some states were challenging this decision.

At the hearing, Sloan-Kettering executives asserted, “There is not a particle of scientific evidence to suggest that Laetrile possesses any anti-cancer properties at all” totally ignoring the three full lab tests of scientific evidence from “the preeminent cancer researcher in America.” As a result of the testimony, Laetrile was officially banned nationwide by 1980.

Afterwards, Dr. Sugiura was asked why Sloan-Kettering was so against Laetrile. “I don’t know,” he replied, “Maybe the medical profession doesn’t like it because they are making too much money.”

When Big Pharma says an alternative treatment has been disproven, this is what they mean.

 

Is Big Pharma Suppressing Information for Profit?

But what about if tests were not done in a Rockefeller-controlled lab. What if one were to do their own tests, build their own case studies, and present them to the appropriate authorities themselves?

One man provided an answer.

Stanislaw Burzynski was a Doctor of Biochemistry who immigrated to the US from Poland in 1970, where he took up a position as a researcher and assistant professor at Baylor University in Houston, Texas. There, he discovered something which he called antineoplastons – naturally occurring “molecular switches” in the human body which, Burzynski asserted, the body used to control cancer growth.

At first, Burzynski’s discoveries were well received by colleagues. In fact, so impressive was his work that he was offered a tenured position in Baylor’s Department of Pharmacology. He should have been thrilled, yet Burzynski knew that if he accepted, he would lose his independence as a researcher. So, he refused the position, instead choosing to found the Burzynski Research Institute in order to continue his work. On his way out the door at Baylor, his boss warned him, “Just wait, Burzynski. They’re going to kick your ass.”

In short order, Burzynski and his clinic were investigated by local medical authorities for using “unapproved medications,” while the Rockefeller-founded American Cancer Society put antineoplastons on its “unproven methods” list, and those who had been funding his research pulled their support.

In 1983, the FDA filed a lawsuit to get him to shut down his operation, and when this failed, FDA agents and federal marshals simply raided the Burzynski Research Institute and seized over 200,000 confidential documents.

Still Burzynski continued on. He raised millions of dollars through his Institute to pay for clinical trials for antineoplastons, money Big Pharma companies are more than happy to spend since they know they will recoup it when their products are patented. By the mid-90s, he was able to provide the FDA with sixty clinical trials, meeting the requirement for their Phase I testing.

For another decade he worked, compiling hundreds more clinical trials, meeting the requirements for Phase II of testing on his own at the cost of millions of dollars.

In 2011, Burzynski began Phase III testing, which involves thousands of participants and can last for years, again, at the cost of many millions of dollars. He was closing in on the finish line by 2013, which is when the FDA stepped in and put a stop to the trials. Their reason? They complained that the Burzynski Research Institute was doing all of the testing, when, of course, this is simply how the FDA approval process works. The only difference is usually the testing is being done by a Big Pharma company.

Finally, in 2017, the FDA cancelled antineoplaston clinical trials for good, refusing Burzynski the right to even conduct the tests. Moreover, Burzynski had his medical license revoked and was fined hundreds of thousands of dollars for his trouble.

The point made by Burzynski and his antineoplastons, by Sloan-Kettering’s Laetrile trials, is simple. It’s a case of ‘you’re damned if you do and damned if you don’t.’ If testing is conducted in a Rockefeller Big Pharma laboratory, it will be repeated and repeated and repeated until it gives the desired results, no matter how manipulated these results might be. And if you conduct the tests yourself, spending millions upon millions of dollars, the results will still not be accepted.

03-04-burzynski-02.webp?w=600&q=75&f=aa0b9051be2d61eaa37d43d89e96624f
Over 60 patients defended Dr. Burzynski stating they were cured by him.

Big Pharma controls the testing, they control approval, they control academic thought. But look closer, and it goes even further than that.

Big Pharma employs 1,270 registered lobbyists in the halls of government, more than two Big Pharma lobbyists for every member of congress, at a cost of over $200 million per year. They also spend tens of millions of dollars every year financing political campaigns – nearly every member of congress is funded by Big Pharma. On top of that, Big Pharma lobbyists and executives are repeatedly put in charge of the government bodies tasked with overseeing the pharmaceutical industry, like the FDA. Simply, the production and sale of medicine is tightly regulated by government, and Big Pharma controls the government.

Is it really so hard to believe that Big Pharma would use its control of academia, science, and government, to suppress valuable information for their own profit?

In reality, suppressing truth for profit is as American as apple pie – from the 1950s, when tobacco companies fought to suppress lung cancer knowledge as people died, to modern times, when oil companies insist that the debate around climate change is still ongoing, even as the consequences scientists promised decades ago are all around.

But pharmaceutical companies? Those purportedly tasked with providing health? Would they really suppress a cure for cancer? And kill people?

Actually, that Big Pharma would knowingly and intentionally kill people for profit is not conspiracy, it is established fact, admitted on record in American courts.

 

How Big Pharma Created the American Opioid Crisis

In October of 2020, Big Pharma flagbearer Purdue Pharma pled guilty in court to criminal charges for its role in the American opioid crisis, agreeing to pay some $8.3 billion in the settlement.

Opioids were a new type of synthetic pain medication that emerged in the early-1990s, which Big Pharma companies like Purdue aggressively promoted while suppressing information about the dangers, most specifically, the extreme addictiveness. Today, not only is chronic pain more prevalent than ever in the US, but nearly a million people have died from opioid overdoses, and another 3 million have fallen victim to addiction.

In pleading guilty at trial, Purdue Pharma admitted on record to having supplied drugs “without legitimate medical purpose.” In other words, the purpose of opioids wasn’t medical, it wasn’t to cure pain; it was to get people addicted so they’d buy more. Purdue even admitted to paying off health insurance companies to deny coverage for alternative care, forcing people to take opioids, and paying off doctors to overprescribe their product to patients.

depositphotos_178773006-stock-photo-macro-of-oxycodone-opioid-tablets.jpg

By February of 2022, four more of the largest Big Pharma companies had reached a $26 billion settlement for their own role in the crisis. These, along with Purdue, are the largest and most powerful pharmaceutical companies in the country, the ones who lobby governments and sit on medical boards. And here they are, on the record, poisoning people for profit.

 

Chemotherapy - The Only Legal "Cure" for Cancer

Apply this knowledge to cancer specifically, and think about what chemotherapy is.

The treatment was first conceptualized by doctors examining soldiers who had been exposed to mustard gas during World War II. Noticing that mustard gas had toxic effects on the blood cells of soldiers, doctors surmised that it could be used against cancer cells.

This was how the first version of chemotherapy, and model for all subsequent versions, was created, from a compound used as an agent of chemical warfare. This is what Big Pharma is telling cancer patients to put in their body.

Of course, it is no big secret that chemotherapy is toxic. Cancer patients are warned that side effects can include everything from vomiting and nausea, to infertility, to organ damage, and even death. They are even warned it can lead to a “second cancer.” In other words, patients are told chemotherapy might treat their cancer, but that it might also cause cancer; it might save their life, but it might also kill them. As one former president of the American Chemical Society succinctly put it, “chemotherapy does much, much more harm than good.”

A bit like opioids …

But that’s the point; there are no profits in the cure. Big Pharma needs people sick, so that people need more and more expensive “treatment.”

In this, the era of Big Pharma is alone in the history of medicine …

Link

The Dinarian On Locals is a labor of love that I pour my heart and soul into during my personal time. Countless hours are dedicated to delivering you the most up-to-date, unfiltered, and authentic news and information. Your support means the world to me, and I invite you to consider making a donation or becoming a dedicated supporter of this project. Any amount of XRP donations can be sent by scanning the QR code below and are greatly appreciated. ~ Namaste🙏🏼The Dinarian

 

 

community logo
Join the TheDinarian Community
To read more articles like this, sign up and join my community today
1
What else you may like…
Videos
Podcasts
Posts
Articles
Thetas Latest Alphacrypto Report 💥
00:00:57
XRP Crushes All Crypto Polls & Bitcoin Maxi Calls Ripple And Stellar Scams
00:15:30
👀 A Top Cancer Expert Wars Of A “Whirlwind Of Cancers.” 👀

Piers Morgan, once a strong proponent of mRNA vaccines, now claims a top cancer expert warned him that Pfizer and Moderna shots have triggered a “whirlwind of cancers.”

00:00:31
👉 Coinbase just launched an AI agent for Crypto Trading

Custom AI assistants that print money in your sleep? 🔜

The future of Crypto x AI is about to go crazy.

👉 Here’s what you need to know:

💠 'Based Agent' enables creation of custom AI agents
💠 Users set up personalized agents in < 3 minutes
💠 Equipped w/ crypto wallet and on-chain functions
💠 Capable of completing trades, swaps, and staking
💠 Integrates with Coinbase’s SDK, OpenAI, & Replit

👉 What this means for the future of Crypto:

1. Open Access: Democratized access to advanced trading
2. Automated Txns: Complex trades + streamlined on-chain activity
3. AI Dominance: Est ~80% of crypto 👉txns done by AI agents by 2025

🚨 I personally wouldn't bet against Brian Armstrong and Jesse Pollak.

👉 Coinbase just launched an AI agent for Crypto Trading
Countries Shift Strategies, Sell Treasury Bonds

Recent data from the U.S. Treasury reveals that China, Japan, and the United Kingdom collectively offloaded $81 billion in Treasury bonds in December. This significant reduction in holdings raises questions about the implications for the U.S. fiscal deficit and increasing borrowing costs.

● What Do the Numbers Say About U.S. Treasury Bonds?

In a noteworthy move, China reduced its Treasury bond portfolio by $9.6 billion, marking a record low of $759 billion—the lowest since 2009. Conversely, Japan enhanced its holdings to $1.0598 trillion by selling $27.3 billion in bonds. The United Kingdom topped the list in divestments, decreasing its portfolio by $44.1 billion to $722.7 billion.

● How is China Diversifying Its Assets?

Starting in November, China began buying gold again, acquiring around ten tons in December alone, resulting in a total of 2,280 tons by the end of the year. This strategy reflects an effort to diversify away from U.S. assets.

Currently, the yield on 10-year U.S. Treasury bonds ...

XRP Price Today: How $2.50 Level Could Decide Its Next Move

Table of Contents:

◇ XRP Technical Analysis and Upcoming Levels

◇ Current Price Momentum

$21.50 Million Worth XRP Outflow
Following the Bybit hack, sentiment across the crypto market has shifted completely toward a bearish phase, weakening assets. Amid this, XRP, the native token of Ripple Labs, has once again neared a crucial support level from the ascending trendline, which it has been testing since the beginning of February 2025.

Considering the current market sentiment and XRP's outlook, the token appears to have absorbed all the bearish pressure and is now recovering.

● XRP Technical Analysis and Upcoming Levels

According to expert technical analysis, as the XRP price reached the trendline support of $2.50 level a significant buying pressure was observed resulting in the formation of a bullish candlestick pattern. Besides this, the recent price drop has not affected XRP’s past ascending triangle price action pattern which it has formed.

Based on recent price action, if XRP holds above the ...

🪙 Jaime Carrasco | Golds Comeback, Silvers Power & The US Debt Reset 🪙

Canadian metals maven Jaime Carrasco joins Denis to deliver a masterclass in decoding the future of investing through the lens of history.

From buying Bitcoin at $5 to why gold isn’t just a commodity—it’s the ultimate form of money—Carrasco lays out the case for how Trump could use precious metals to reshape the financial system.

He dives into the silver supply crunch, taps into how Mexico could flip the script on global trade, and questions whether Trump is a modern-day Roosevelt with plans to reset the U.S. debt clock.

Discover why chasing quick returns could be the biggest mistake of younger generations and why if you don’t own gold, you don’t know history or economics.

post photo preview
The Dawn of DeFi: The Hidden War for a Decentralized Future
👉 DON'T FADE THIS ARTICLE~ Crypto Michael AKA "The Dinarian"

The below article is NOT financial advice, it is being broadcast for entertainment purposes only. You should DO YOUR OWN RESEARCH and NEVER invest any more than you are willing to lose. On that note, THIS ARTICLE AND THE UNDERLYING ASSET DISCUSSED COULD CHANGE YOUR LIFE FOR THE BETTER FOREVER! You SHOULD pay close attention as this MAY BE THE MOST IMPORTANT article you could ever have read, unless you were fortunate enough to read the Bitcoin whitepaper and had invested in it back in 2008. The asset I am about to present to you, COULD EASILY FLIP BITCOIN! ESPECIALLY WITH TODAYS ADMINISTRATION IN PLACE!

~ Namasté 🙏 Crypto Michael AKA "The Dinarian"

Attempted Theft of the World's Most Valuable Property, SEC Lawfare & The ETHgate Scandal

It is widely accepted that the media often spreads misinformation and hides any truth that challenge the establishments narratives. Well, this is one of those hidden truths...
 
Loans without Banks, Trades without Exchanges, Contracts without Lawyers. Peer to Peer Capital Markets disrupts traditional finance by removing middlemen and counter-party risk, enabling you to become your own bank by holding the keys to it all in your own privately held digital wallet.
 
To what lengths do you think the establishment would go to defend their control of the financial system? A system seemingly ripe with market manipulation, naked shorts, money laundering and regulatory capture.

The Myth of Open Source

For context, in the realm of open source, major corporations can engage in Intellectual Property theft by using open source projects to gain insights, technology, or legal protections without fully reciprocating to the community. Companies might contribute code to an open source project, only to later use that same code in commercial products, extending it with enhancements, essentially using open source as a low-cost R&D resource. Patents are crucial here, serving as a defense mechanism. Although open-source licenses cover copyrights, they don't extend to patents, meaning that companies holding patents can enforce legal protections against unauthorized commercial use, ensuring that any commercial application of their patented technology within open-source software requires proper licensing or recognition. This protection has historically led to the hyper-growth of industries like mobile phones and the internet, where patented technologies could be safely shared and built upon, promoting innovation and market expansion.
 

Validating Inventorship

In fields such as technology, pharmaceuticals, and manufacturing, patents are vital for safeguarding new inventions, with Nikola Tesla's extensive patent portfolio serving as a testament to his contributions to science.
 
However, Tesla's revolutionary inventions, like the Wardenclyffe Tower which aimed at providing free wireless energy, faced fierce opposition due to their potential to disrupt established control over energy markets. Financially sabotaged by investors like J.P. Morgan, legally challenged through "the war of currents" by Thomas Edison's promotion of the less efficient Direct Current system, and undermined by media smear campaigns, Tesla's work was systematically suppressed. After his death, the FBI's seizure of his documents further suggests efforts to control or conceal his ideas that could disrupt centralized energy distribution, illustrating how innovation can be stifled to maintain existing power structures.
 
Could this type of suppression still be happening today?
 

The Genesis of Decentralized Finance

Reggie Middleton first introduced Distributed Finance what would later become known as Decentralized Finance (DeFi), in 2013 when he invented and patented technologies under the title "Devices, systems, and methods for facilitating low trust and zero trust value transfers." This included groundbreaking concepts like programmable Smart Contracts, Swaps, Tokenized Assets, NFTs, Stable Coins, Digital Wallets, and even underpin Central Bank Digital Currencies (CBDCs).
 
 
Called by many as "The Most Valuable Property in the World", his patents US11196566B2, US11895246B2, JP6813477B2, JP7204231B2, JP7533974B2, & JP7533983B2 have been cited over 138 times by major financial institutions, underscoring their foundational role in the blockchain industry.
 

His patents cover:

  • Trustless Peer-to-Peer Value Transfers: Systems for enabling decentralized and secure value transfers between parties without the need for intermediaries. Applicable to cryptocurrency transactions, DeFi platforms, and digital payment systems.
  • Decentralized Financial Systems (DeFi): Methods and devices that facilitate decentralized trading, lending, borrowing, and yield generation. Impacting decentralized exchanges (DEXs) like Uniswap, SushiSwap, and similar platforms.
  • Smart Contracts: Implementation of self-executing contracts on blockchain networks, used to automate agreements and enforce conditions without intermediaries. Essential for platforms such as Ethereum, Cardano, and other Layer-1 and Layer-2 blockchain protocols.
  • Tokenized Asset Trading: Methods for creating, transferring, and trading tokenized assets, including cryptocurrencies, non-fungible tokens (NFTs), and digital securities. Platforms like OpenSea, Rarible, and asset tokenization platforms may fall within the scope.
  • Cryptographic Security and Wallet Systems: Systems for securing digital assets using cryptographic methods, including cold storage, multi-signature wallets, and multi-party computation (MPC). Potential overlaps with services offered by companies like Coinbase, Kraken, Gemini, and institutional custody providers.
  • Decentralized Identity and Verification Systems: Technologies for managing and verifying digital identities on decentralized networks, including for KYC (Know Your Customer) purposes. Likely touching on identity solutions like Civic, BrightID, and Blockstack.
  • Blockchain-Based Voting and Governance: Systems for implementing decentralized voting, governance, and consensus mechanisms, foundational to DAO (Decentralized Autonomous Organizations). Relevant to governance platforms like Aragon, Snapshot, and MakerDAO.
  • AI Economic Agentic Computing: First introduced by the VeADIR Platform refers to the application of autonomous agents in economic systems, where software entities can make decisions, negotiate, and execute transactions independently. These agents use artificial intelligence to analyze market data, predict trends, and optimize economic activities like trading, resource allocation, and supply chain management. Used by OpenAi, Claude Sonnet, Meta and xAI.

The societal value of these patents to disrupt traditional financial models and fintech business practises, by essentially removing the banks as middlemen, create significant economic incentives to suppress his work.
 

True Decentralization

Current Decentralized Exchanges (DEXs) often fall short of being truly decentralized due to various practical and structural limitations. Although DEXs leverage blockchain technology and smart contracts to enable trading without a central authority, aspects like governance, liquidity, and user interface can introduce centralization. Governance tokens might be concentrated in the hands of a few, influencing decision-making unevenly. The frontend, controlled by developers, represents a centralized point of control or potential failure. Liquidity pools can be dominated by a handful of large providers, leading to centralized liquidity dynamics. Some DEXs implement regulatory compliance like KYC/AML, which inherently involves centralized oversight. The use of layer-2 solutions for scalability might also undermine decentralization if not fully autonomous.
 
However, patents like US11196566B2 and US11895246B2 could pave the way for true decentralization by introducing innovations in blockchain interoperability and decentralized governance mechanisms. These patents potentially offer solutions for more evenly distributed control over exchange operations, enhancing the autonomy and distribution of decision-making, thus moving closer to genuine decentralization in the DEX ecosystem, which can be expanded to other industries like Healthcare, Supply Chain, or any other industry that trades value.
 

Who is Reggie Middleton?

Reggie Middleton, through his BoomBustBlog, became a notable figure in financial analysis, particularly for his early and accurate predictions regarding the collapses of Lehman Brothers and Bear Stearns during the 2008 financial crisis. His blog was renowned for providing in-depth, contrarian insights into economic trends, investment opportunities, and corporate vulnerabilities. Reggie won the CNBC's stock draft consecutively for two years, and appeared on major financial news networks like CNBC, BBC and Bloomberg where he discussed market trends, his forecasts, and the implications of financial strategies adopted by major firms. His track record has undeniably positioned him as a significant voice in the financial commentary space.
 

Reggie's work gained public attention when he appeared on the Keiser Report and CNBC in 2014, premiering his innovations built on the Bitcoin blockchain called "Ultracoin", two years before Ethereum captured the crypto limelight.
 
 
His vision was to create sound markets for a financial ecosystem where loans could be issued without banks, trades executed without exchanges, and contracts enforced without lawyers, aiming to disintermediate traditional finance by removing the middleman that doesn't add value.
 

 
In 2014, Reggie pioneered a simple Apple trade using a Pure Bitcoin Wallet: The Ultracoin Client.
Ultracoin later renamed VERI short for “Veritaseum” meaning "of truth", was the
first to market in tokenizing precious metals, offering VeGold, VeSilver and even tokenized fiat currencies or so called "Stablecoins". Veritaseum also introduced VeRent creating yield through P2P lending, and the revolutionary VeADIR platform, an autonomous, blockchain-powered research platform that independently evaluates and acts on dynamic research in real-time, communicates in machine language, and operates by purchasing, analyzing, and distributing insights on various assets while allowing VERI token holders to access and trade this research.
 
In 2018 he created the worlds first Gold Denominated Blockchain Mortgage
with traditional written note, mortgage as well as a smart contract on a public blockchain, both of whom incorporate each other by reference. The transaction had traditional title insurance and the note was recorded with the county clerk. The mortgage was denominated in Veritaseum's VeGold product, a digital form of gold in bearer form, fully transferable and redeemable upon demand.
 
 
Merely a few examples of groundbreaking products offered by Veritaseum.
 

Coinbase's Challenge: The Patent Infringement Suit

Coinbase, a dominant force in the cryptocurrency exchange market, enlisted the services of Perkins Coie, one of the largest patent law firms, to contest the validity of Reggie Middleton's patents.
They launched an Inter Partes Review (IPR) at the Patent Trials and Appeals Board (PTAB), arguing that Middleton's patents lacked novelty. An overwhelming 85% of patents are invalidated through this process. However, Coinbase's challenge was denied along with the appeal, thereby upholding and strengthening the validity of Reggie's patents.
This IPR challenge came after Veritaseum sued both Coinbase and Circle USDC for $350 million each over patent infringement. Unfortunately, Reggie's patent attorney and close friend passed away during this suit, so the cases has been dismissed without prejudice, meaning they can be negotiated or the cases reopened at any time. This leaves Coinbase in a precarious position, especially if shareholders have not been properly informed of this risk.
 
This lawsuit details how Coinbase's infrastructure, specifically its Ethereum and Solana validator nodes, engage with client devices to facilitate transactions. Exhibit #3 meticulously outlines the patent's claims, detailing the roles of computing devices, the use of memory for key pair storage, network interfaces for transaction terms, and the generation and dissemination of transaction data records. It provides concrete examples such as the processing of NFT transactions on Ethereum and the management of transaction fees on Solana, supported by in-depth references to code and API interactions. Furthermore, the exhibit explains the verification of transactions through an external state, illustrating how Coinbase's technology aligns with the patent's principles for decentralized transaction processing without a central authority.
 

SEC's Intervention: A Turning Point

In 2019, with promising negotiations on the horizon with both the Jamaican and the Nigerian Stock Exchanges for digital asset platforms, Reggie's world was turned upside down.
 
The SEC accused Reggie of fraud, alleging he misled investors about the functionality of Veritaseum's VeADIR platform, which the SEC ordered to be shut down following a live demonstration. The SEC also made claims on the validity of Reggie's patent applications, which have since been approved by both the USPTO and the Japan Patent Office. Oddly enough, the SEC may actually infringe on these very patents through the disgorgement and storage of seized crypto tokens.
 
Despite Veritaseum's cooperation with the SEC over a two-year period, along with a detailed response addressing the SEC's allegations, and not one token holder claiming to be defrauded, these allegations still led to a Temporary Restraining Order (TRO) that froze millions in assets, destroying the company's operations, and forcing a consent judgment "neither confirming or denying the allegations". The SEC would top it all off with a gag order that barred Reggie from publicly discussing the matter.
 
Keep in mind, the SEC is claiming jurisdiction by calling Utility Tokens "Digital Asset Securities" but recently SEC Commissioner @HesterPeirce stated:
 
"...by using imprecise language we've been able to suggest the token itself is a security, apart from that investment contract, which has implications for Secondary Sales, it has implications for who can list it...
 
We've fallen down on our duty as a regulator not to be precise. So, tucking into a footnote that yes we admit that now that the TOKEN ITSELF IS NOT A SECURITY, that is something we should have admitted long ago and then started wrestling with the difficult questions."
 
 
This calls into question if the SEC even had jurisdiction to bring forth this case to begin with. The Veri Community would later challenge the SEC's unproven allegations against Reggie with
a Dossier supporting the Vacating or Setting Aside of this case, and suggesting possible misconduct by the SEC.
 

Allegations of SEC Misconduct:

  • Misrepresentation of Facts: Assertions that the SEC deliberately mischaracterized the
    functionality of the VeADIR platform, along with the patents and their value, by labeling them as lacking novelty and part of fraudulent activities.
  • Misleading Evidence: The SEC's use of declarations from Patrick Doody and Roseann Daniello, which contained misleading information about the personal ownership of a Kraken account used to misappropriate funds. Doody would later correct his statement, but the SEC did not update the court with this new information, potentially misleading the judicial process.
  • Conflict of Interest: Doody's undisclosed financial interests in the digital asset space through Lily Pad Capital LLC could suggest a bias in his testimony, which was pivotal in obtaining the TRO.
  • Coercion and Intimidation: Witnesses like Lloyd Cupp and John Doe provided affidavits claiming coercion by SEC attorneys to alter their testimonies, pointing towards witness tampering and intimidation.

placeholder

Summary Articles of the Bar Complaint and RICO Dossier

 

Comparisons with the SEC Misconduct in the DEBT Box Case

The DEBT Box case shares a troubling parallel with the Veritaseum case. In both cases a Temporary Restraining Order (TRO) freezing funds was issued using dubious evidence which suppressed the ability to defend themselves. This behavior was already admonished by five US Senators
in a letter to Commissioner Gary Gensler in which the SEC presented misleading claims in this now high-profile cryptocurrency case.
 
"Regardless of whether Commission staff deliberately misrepresented evidence or unknowingly presented false information, this case suggests other enforcement cases brought by the Commission may be deserving of scrutiny. It is difficult to maintain confidence that other cases are not predicated upon dubious evidence, obfuscations, or outright misrepresentations."
 
Given the similarities in alleged procedural misconduct between the cases, it raises systemic questions about the SEC’s litigation approach in cryptocurrency matters.
 
 
This parallel underscores a potential agency-wide issue that could involve either implicit biases against crypto companies or an explicit strategy to pursue aggressive, potentially misleading tactics in court.
 

Is The Fox Guarding the Hen House?

In a significant development, the Attorney Grievance Committee (AGC) has decided to forward a complaint against SEC attorney Jorge Tenreiro to the SEC's Office of General Counsel (OGC) for investigation. This controversial move suggests a potential conflict of interest, given that the OGC is part of the SEC, the very agency where Tenreiro was recently promoted to Chief Litigation Counsel. The complaint, filed by the Veri community, accuses Tenreiro of misconduct including alleged coercion, witness tampering, and misrepresentation during SEC investigations. The Veri Community argues that this decision undermines the integrity of the legal process, as the OGC's role is to provide legal advice and defend the SEC, not to independently investigate its own employees. This raises questions about the impartiality and transparency of the disciplinary process for attorneys, especially when it involves high-profile figures like Tenreiro.
 
"As noted in re Rowe, 80 N.Y.2d 336 (1992), the public’s confidence in the legal profession depends on transparent and impartial disciplinary processes. Delegating oversight to the SEC, where Mr. Tenreiro remains a senior official and where the OGC has a clear institutional stake, jeopardizes this confidence and risks the appearance of protectionism.”
 
The VeriDAO has submitted a response letter to the AGC along with creating a PDF generator
to help the estimated 100 complainants and anyone else interested in requesting the AGC to reconsider this action.
 

Legal and Judicial Trials

The legal battles would only continue for Reggie. The case of Hall v. Middleton, in which Hall, a 1% shareholder sued Reggie, raises concerns of judicial bias and procedural mishandling. In this case, Reggie was denied Due Process and barred from presenting crucial evidence or calling witnesses due to his former attorneys' "Office Failures" that missed deadlines to submit evidence without the knowledge of Reggie or the firm Brundidge & Stanger that outsourced his counsel as detailed in their affirmations.
 
"In my many years of practice it is a rare instance where I have witnessed an attorney intentionally not file critical documents as required by Court Order without the permission or knowledge of his client, who had an established and fully developed attorney client-relationship with said attorney, and then misrepresent that the requirements of the Court Order were being satisfied. This is one of those instances and I hope not to see another."
~ Carl Brundidge
The judge ruled that Reggie must:
  • Pay a $1M fine to his company Veritaseum Inc., in which he owns 99%
  • The plaintiff was awarded costs of $495k against Veritaseum Inc.
  • The Judge ordered Patents (filed before the creation of Veritaseum Inc.) to be assigned to the company without compensation.

Attorney's "Office Failures":

  • Sheridan England missed critical deadlines, resulting in the striking of exculpatory evidence. England’s inaction or inadequate defense exacerbated Middleton’s legal vulnerability, directly leading to adverse outcomes.

Judge Schecter’s Conduct:

  • Ignoring Exculpatory Evidence: Despite knowledge of its existence, Schecter struck Middleton’s post-trial memorandum.
  • Procedural Bias: The judge’s decisions systematically favored Hall, including allowing him to collect attorney fees from Middleton personally, contrary to the principles of derivative law.
  • Forced Patent Transfers: Schecter’s order to transfer patents to an underfunded entity (Veritaseum) which were court restrained by the same judge, rendering them defenseless against attacks and IP theft.
This ordeal was compounded when Reggie was held in Contempt for using personal funds (while Veritaseum’s funds were court-restrained) to successfully defend his patents against an IPR challenge by Coinbase in the PTAB of the USPTO in an attempt to invalidate these patents. The Forced Patent Expropriation to Veritaseum without compensation or the ability to defend them could be seen as coordinated as it benefited very large competitors seeking to avoid licensing fees or infringement claims, or possibly even IP Theft.

ETHgate: The Broader Conspiracy Allegations

Parallel to Middleton's struggles, "ETHgate" emerged, involving allegations by Ethereum co-creator @StevenNerayoff. Nerayoff claimed a government conspiracy aimed at controlling or monopolizing cryptocurrency development by targeting key figures. This narrative suggested that by attacking innovators (like Reggie Middleton as the Veri Community contends), the SEC might have indirectly cleared a path for Ethereum, which, despite its decentralized claim, benefited from a regulatory environment less scrutinized than its competition.
 
The term "ETHgate" encapsulates the belief that Ethereum's "Free Pass" from regulatory scrutiny might not just be due to its technological merits but also due to strategic regulatory maneuvers, where attacking smaller or less established DeFi projects could safeguard larger, more influential platforms like Ethereum.
 
Back in 2021, @JohnEDeaton1 from @CryptoLawUS explained XRP's side of Ethereum's "Free Pass". More recently, further SEC RICO Claims are insinuated in "RIGGED from the start" a documentary by @Fruition_News , along with posts by @KuwlShow and the XRParmy involving the SEC, Ethereum, a16z, and Consensys surrounding the Bill Hinman speech. Active FOIA requests by @EleanorTerrett seek to shed light on meetings between Hinman and Ethereum members.
 
Given the SEC protection of ETH and the high probability of Ethereum infringing on Reggie Middleton's patents as meticulously detailed in Exhibit #3 of the Coinbase case, is it ridiculous to believe Reggie Middleton could have been targeted?
 

 

Community Support: The Backbone of Resilience

Despite the SEC's narrative labeling them as "The Defrauded," the Veritaseum community rallied around Reggie.
 
                          SmartMetal with embedded NFT avalaible through VeriDAO.io
 
Financially devastated and with his funds frozen, Reggie faced foreclosure and was threatened with jail time after contempt charges for defending his patents using personal funds. In a remarkable show of support, the Veri Community rallied, raising an impressive $149,000 in less than two weeks to cover the fine while the case is under appeal.
 
They funded legal battles largely through donations and more recently with innovative means like NFT silver rounds called SmartMetal using Reggie's patented technologies, underscoring their belief in his vision. The first minted round was auctioned off for an astonishing $14,000 won by "M S"
 
"There is no better witness to the veracity of any defense than the alleged defrauded defending the alleged fraud at their own expense"
~ The Veri Community
This community support was not just financial but also moral, with efforts such as an Amicus Brief in the case against XRP, a No Action Letter (NAL) seeking clarity on secondary market sales of tokens, a Bar Complaint against the SEC's newly promoted Chief Litigation Counsel, and the @dao_veri's
#ProjectSunlight The SEC RICO Revelation.
 

A Call for a New Regulatory Paradigm

 
Reggie Middleton's saga is emblematic of the challenges faced by pioneers in the blockchain and DeFi arenas. His patents, now granted, underscore their foundational nature, yet the path to their recognition was marred by legal battles, suggesting a systemic issue where the regulatory framework might not fully comprehend or support emerging tech. His resilience, supported by an unwavering community and the validation of his intellectual property, underscores the need for a regulatory environment that fosters rather than stifles innovation. As blockchain technology continues to evolve, Reggie's story serves as a critical reference for balancing innovation with legal and ethical governance, ensuring that the future of finance remains open to all, not just those with the resources to navigate the legal maze.
 
For more information visit https://veridao.io/
 
 
I know what everyones question is, "HOW CAN I GET MY HANDS ON THE $VERI TOKEN BEFORE EVERYTHING GETS REVERSED AND RELEASED BACK TO THE COMMUNITY?" 
 
Your in luck: Mark is a trusted source, longtime Veri Vet that beta tested the VeADIR platform. Simply follow the thread below. I highly advise picking up a few, and tuck them away! This is the token that could literally FLIP BITCOIN $100k and beyond!
 
 

The information provided in this video, including but not limited to documents regarding legal matters, is for informational purposes only. It does not constitute legal (or any other) advice, and no warranties or representations are made regarding the accuracy, completeness, or fitness of the information for any specific purpose. VeriDAO and its operators do not act as attorneys or legal, financial or technical professionals or advisors and are not responsible for any actions taken or decisions made based on the content provided. Users should seek independent legal counsel for any legal advice or guidance. By watching this video, you agree that VeriDAO and its operators shall not be held liable for any damages or legal consequences arising from the use or misuse of the information contained herein.

Link

 

Disclaimer:
 
The content provided in this document is intended strictly for informational and educational purposes only. This document constitutes a research opinion and should be regarded as such. All claims, statements, allegations, and opinions contained within are based on publicly available information and are allegations unless and until proven in a court of law. The authors expressly disclaim any representation or warranty regarding the truthfulness, accuracy, completeness, fitness for a particular purpose, or durability of the information contained herein.
 
The authors of this document are not licensed attorneys or legal professionals and do not claim to provide legal, financial, or professional advisory services. Nothing in this document should be construed as legal advice, legal opinion, or any form of licensed advisory counsel. If you require legal assistance or professional advice, you are strongly encouraged to consult a licensed attorney or qualified expert in the relevant field. The authors are laypersons presenting research-based opinions, and as such, this document should not be relied upon to make any decisions of legal, financial, or professional significance.
 
The authors make no guarantees, express or implied, regarding the completeness or reliability of the information presented. No warranties of any kind are offered regarding the accuracy, validity, timeliness, or completeness of any information within this document. The information may contain errors or inaccuracies, and any use of it is entirely at your own risk.
 
Furthermore, this document may contain statements of belief, criticism, or commentary, and all such statements are offered solely as opinions protected under the principles of free speech. The authors disclaim liability for any interpretation that may be construed as libel, slander, or defamation, as the document aims to present alleged facts and subjective opinions for educational research purposes only. All statements about individuals, organizations, or entities should be understood as unproven allegations, and readers are urged not to interpret them as established facts.
 
The authors will not be liable for any damages, losses, or legal consequences that arise from the use, misuse, or reliance on the information provided herein. No responsibility is assumed for any actions or decisions that any party may make based on this document. The reader assumes full responsibility for any and all consequences that may arise from using the information contained in this document.
 
By accessing and using this document, you agree that neither the authors nor any affiliated parties shall be held liable for any direct, indirect, incidental, special, consequential, or punitive damages resulting from your use of this information. The authors reserve the right to update or revise the information in this document at any time without notice, but they are under no obligation to do so.
Finally, any statements regarding individuals, entities, or organizations are not intended to malign, defame, or harm the reputation of those mentioned. Any resemblance to real individuals or incidents is purely coincidental, unless otherwise explicitly stated, and the authors urge readers to exercise caution and discernment when interpreting the information presented.
 
This document is a work-in-progress, part of an ongoing investigative process, and should not be treated as definitive or final. Readers are encouraged to independently verify the information and seek professional advice before acting on any information herein.
 
Read full Article
post photo preview
SEC Drops Dealer Rule Appeal

 The US Securities and Exchange Commission (SEC) has abandoned its appeal of a contentious dealer rule designed to classify digital asset operations as regulated securities dealers broadly.

  • A federal judge ruled that the SEC had exceeded its authority by potentially categorizing nearly any participant in buying and selling securities as a dealer.

  • This decision is part of a broader reset in the SEC's approach to digital assets under new leadership.

  • The agency’s move to drop the appeal, amid concerns that continued litigation could reduce Treasury market liquidity and increase taxpayer costs.

  • Additionally, the SEC recently sought to pause its enforcement actions against Binance, indicating its readiness to resolve disputes through alternative means.

  • Blockchain Association CEO welcomed the dismissal, expressing hope for more productive discussions between regulators and the crypto industry as the US embraces a friendlier regulatory framework for digital assets.

What’s next: With acting chairman Mark Uyeda overhauling senior staff and legal strategies, the SEC is shifting away from its historically adversarial stance, a policy long associated with former chairman Gary Gensler.

For builders and investors: The new approach encourages constructive conversations between regulators and industry players, potentially leading to clearer guidelines and a more predictable operating landscape for both builders and investors.

Link

Read full Article
post photo preview
Tether Teams Up With US Lawmakers on Stablecoin Rules

Tether is reportedly working with members of the US House Financial Services Committee, specifically Representatives Bryan Steil and French Hill, to shape federal stablecoin regulations.

  • This includes contributing to the STABLE Act introduced by both lawmakers in early February, as well as offering input on two additional stablecoin bills.

  • According to Tether CEO Paolo Ardoino, the company wants its perspective heard during the legislative process and is prepared to adapt to US rules.

  • The new rules may include requirements like monthly reserve audits and 1:1 collateral backing.

  • Tether’s involvement comes amid broader regulatory discussions, including meetings between crypto industry leaders and the SEC, and the push to bring stablecoins onshore.

  • Meanwhile, the Federal Reserve is warming to stablecoins as a means of preserving the US dollar’s global dominance but remains concerned about risks such as de-pegging events and market fragmentation.

What’s Next: Tether’s collaboration with lawmakers suggests that stablecoin regulations could soon take a more defined shape and may introduce stricter compliance measures, including mandatory audits and full collateral backing.

Why it Matters: If lawmakers strike the right balance, stablecoins could cement their role in global finance, benefiting both the crypto industry and the broader economy.

Our Take: If Tether and other stablecoin issuers adapt to US regulatory frameworks, it could bring legitimacy to the stablecoin sector, encourage institutional adoption, and integrate crypto more deeply into the traditional financial system.

Link

Read full Article
See More
Available on mobile and TV devices
google store google store app store app store
google store google store app tv store app tv store amazon store amazon store roku store roku store
Powered by Locals